(NBIX) Neurocrine Biosciences - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US64125C1099
Stock: Neurological Drugs, Endocrine Drugs, Psychiatric Drugs
Total Rating 47
Risk 86
Buy Signal -0.55
| Risk 5d forecast | |
|---|---|
| Volatility | 33.2% |
| Relative Tail Risk | -14.3% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.61 |
| Alpha | 4.65 |
| Character TTM | |
|---|---|
| Beta | 0.450 |
| Beta Downside | -0.806 |
| Drawdowns 3y | |
|---|---|
| Max DD | 42.89% |
| CAGR/Max DD | 0.26 |
EPS (Earnings per Share)
Revenue
Description: NBIX Neurocrine Biosciences March 05, 2026
Neurocrine Biosciences Inc. (NBIX) is a biotechnology company focused on developing and commercializing treatments for neurological, psychiatric, endocrine, and immunological disorders.
The companys product portfolio includes treatments for tardive dyskinesia, endometriosis, uterine fibroids, and congenital adrenal hyperplasia. NBIX also has a pipeline of drug candidates in clinical development for various conditions, including movement disorders, major depressive disorder, schizophrenia, epilepsy, and Alzheimers disease. The biotechnology sector is characterized by lengthy and expensive research and development processes, often spanning over a decade from discovery to market.
NBIX employs a business model that includes both proprietary drug development and strategic collaborations. They have licensing and collaboration agreements with several pharmaceutical companies, which can provide funding, shared development costs, and broader market access. For further details on NBIXs specific drug pipeline and market performance, ValueRay offers in-depth analysis.
Headlines to watch out for
- INGREZZA sales growth drives revenue expansion
- Pipeline development success impacts future revenue
- Regulatory approvals for new drugs create market opportunities
- Collaboration agreements influence R&D costs and revenue sharing
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income: 478.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 1.18 > 1.0 |
| NWC/Revenue: 62.20% < 20% (prev 51.67%; Δ 10.53% < -1%) |
| CFO/TA 0.17 > 3% & CFO 782.7m > Net Income 478.6m |
| Net Debt (-297.7m) to EBITDA (719.1m): -0.41 < 3 |
| Current Ratio: 3.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.5m) vs 12m ago -0.39% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 68.51% > 50% (prev 63.34%; Δ 5.18% > 0%) |
| Interest Coverage Ratio: -42.01 > 6 (EBITDA TTM 719.1m / Interest Expense TTM -16.4m) |
Altman Z'' 4.30
| A: 0.38 (Total Current Assets 2.52b - Total Current Liabilities 743.4m) / Total Assets 4.63b |
| B: 0.10 (Retained Earnings 447.7m / Total Assets 4.63b) |
| C: 0.17 (EBIT TTM 689.0m / Avg Total Assets 4.18b) |
| D: 0.33 (Book Value of Equity 460.9m / Total Liabilities 1.38b) |
| Altman-Z'' Score: 4.30 = AA |
Beneish M -2.85
| DSRI: 1.18 (Receivables 686.8m/479.1m, Revenue 2.86b/2.36b) |
| GMI: 1.00 (GM 98.18% / 98.56%) |
| AQI: 0.90 (AQ_t 0.34 / AQ_t-1 0.38) |
| SGI: 1.21 (Revenue 2.86b / 2.36b) |
| TATA: -0.07 (NI 478.6m - CFO 782.7m) / TA 4.63b) |
| Beneish M-Score: -2.85 (Cap -4..+1) = A |
What is the price of NBIX shares?
As of March 13, 2026, the stock is trading at USD 129.54 with a total of 751,457 shares traded.
Over the past week, the price has changed by -1.43%, over one month by +3.80%, over three months by -16.37% and over the past year by +17.15%.
Over the past week, the price has changed by -1.43%, over one month by +3.80%, over three months by -16.37% and over the past year by +17.15%.
Is NBIX a buy, sell or hold?
Neurocrine Biosciences has received a consensus analysts rating of 4.48.
Therefore, it is recommended to buy NBIX.
- StrongBuy: 15
- Buy: 7
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the NBIX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 178 | 37.4% |
| Analysts Target Price | 178 | 37.4% |
NBIX Fundamental Data Overview March 12, 2026
P/E Trailing = 27.7983
P/E Forward = 21.0526
P/S = 4.545
P/B = 4.0052
P/EG = 0.3571
Revenue TTM = 2.86b USD
EBIT TTM = 689.0m USD
EBITDA TTM = 719.1m USD
Long Term Debt = 415.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 51.3m USD (from shortTermDebt, two quarters ago)
Debt = 415.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -297.7m USD (from netDebt column, last quarter)
Enterprise Value = 11.94b USD (13.00b + Debt 415.3m - CCE 1.48b)
Interest Coverage Ratio = -42.01 (Ebit TTM 689.0m / Interest Expense TTM -16.4m)
EV/FCF = 15.94x (Enterprise Value 11.94b / FCF TTM 748.7m)
FCF Yield = 6.27% (FCF TTM 748.7m / Enterprise Value 11.94b)
FCF Margin = 26.17% (FCF TTM 748.7m / Revenue TTM 2.86b)
Net Margin = 16.73% (Net Income TTM 478.6m / Revenue TTM 2.86b)
Gross Margin = unknown ((Revenue TTM 2.86b - Cost of Revenue TTM 52.1m) / Revenue TTM)
Tobins Q-Ratio = 2.58 (Enterprise Value 11.94b / Total Assets 4.63b)
Interest Expense / Debt = 11.97% (Interest Expense 49.7m / Debt 415.3m)
Taxrate = 35.80% (85.7m / 239.4m)
NOPAT = 442.4m (EBIT 689.0m * (1 - 35.80%))
Current Ratio = 3.39 (Total Current Assets 2.52b / Total Current Liabilities 743.4m)
Debt / Equity = 0.13 (Debt 415.3m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -0.41 (Net Debt -297.7m / EBITDA 719.1m)
Debt / FCF = -0.40 (Net Debt -297.7m / FCF TTM 748.7m)
Total Stockholder Equity = 2.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.46% (Net Income 478.6m / Total Assets 4.63b)
RoE = 16.67% (Net Income TTM 478.6m / Total Stockholder Equity 2.87b)
RoCE = 20.96% (EBIT 689.0m / Capital Employed (Equity 2.87b + L.T.Debt 415.3m))
RoIC = 15.40% (NOPAT 442.4m / Invested Capital 2.87b)
WACC = 7.57% (E(13.00b)/V(13.42b) * Re(7.57%) + D(415.3m)/V(13.42b) * Rd(11.97%) * (1-Tc(0.36)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.10%
[DCF] Terminal Value 82.66% ; FCFF base≈672.1m ; Y1≈829.1m ; Y5≈1.41b
[DCF] Fair Price = 263.1 (EV 26.11b - Net Debt -297.7m = Equity 26.41b / Shares 100.4m; r=7.57% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 70.41 | EPS CAGR: 99.90% | SUE: 0.06 | # QB: 0
Revenue Correlation: 97.77 | Revenue CAGR: 28.93% | SUE: 0.85 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.99 | Chg7d=+0.000 | Chg30d=-0.231 | Revisions Net=-7 | Analysts=14
EPS current Year (2026-12-31): EPS=7.95 | Chg7d=+0.000 | Chg30d=-1.193 | Revisions Net=-13 | Growth EPS=+24.4% | Growth Revenue=+20.4%
EPS next Year (2027-12-31): EPS=9.71 | Chg7d=+0.124 | Chg30d=-1.016 | Revisions Net=-10 | Growth EPS=+22.1% | Growth Revenue=+10.6%
[Analyst] Revisions Ratio: -0.78 (1 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = +19.1% (Analyst 23.5% - Implied 4.4%)
P/E Forward = 21.0526
P/S = 4.545
P/B = 4.0052
P/EG = 0.3571
Revenue TTM = 2.86b USD
EBIT TTM = 689.0m USD
EBITDA TTM = 719.1m USD
Long Term Debt = 415.3m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 51.3m USD (from shortTermDebt, two quarters ago)
Debt = 415.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -297.7m USD (from netDebt column, last quarter)
Enterprise Value = 11.94b USD (13.00b + Debt 415.3m - CCE 1.48b)
Interest Coverage Ratio = -42.01 (Ebit TTM 689.0m / Interest Expense TTM -16.4m)
EV/FCF = 15.94x (Enterprise Value 11.94b / FCF TTM 748.7m)
FCF Yield = 6.27% (FCF TTM 748.7m / Enterprise Value 11.94b)
FCF Margin = 26.17% (FCF TTM 748.7m / Revenue TTM 2.86b)
Net Margin = 16.73% (Net Income TTM 478.6m / Revenue TTM 2.86b)
Gross Margin = unknown ((Revenue TTM 2.86b - Cost of Revenue TTM 52.1m) / Revenue TTM)
Tobins Q-Ratio = 2.58 (Enterprise Value 11.94b / Total Assets 4.63b)
Interest Expense / Debt = 11.97% (Interest Expense 49.7m / Debt 415.3m)
Taxrate = 35.80% (85.7m / 239.4m)
NOPAT = 442.4m (EBIT 689.0m * (1 - 35.80%))
Current Ratio = 3.39 (Total Current Assets 2.52b / Total Current Liabilities 743.4m)
Debt / Equity = 0.13 (Debt 415.3m / totalStockholderEquity, last quarter 3.25b)
Debt / EBITDA = -0.41 (Net Debt -297.7m / EBITDA 719.1m)
Debt / FCF = -0.40 (Net Debt -297.7m / FCF TTM 748.7m)
Total Stockholder Equity = 2.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.46% (Net Income 478.6m / Total Assets 4.63b)
RoE = 16.67% (Net Income TTM 478.6m / Total Stockholder Equity 2.87b)
RoCE = 20.96% (EBIT 689.0m / Capital Employed (Equity 2.87b + L.T.Debt 415.3m))
RoIC = 15.40% (NOPAT 442.4m / Invested Capital 2.87b)
WACC = 7.57% (E(13.00b)/V(13.42b) * Re(7.57%) + D(415.3m)/V(13.42b) * Rd(11.97%) * (1-Tc(0.36)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.10%
[DCF] Terminal Value 82.66% ; FCFF base≈672.1m ; Y1≈829.1m ; Y5≈1.41b
[DCF] Fair Price = 263.1 (EV 26.11b - Net Debt -297.7m = Equity 26.41b / Shares 100.4m; r=7.57% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: 70.41 | EPS CAGR: 99.90% | SUE: 0.06 | # QB: 0
Revenue Correlation: 97.77 | Revenue CAGR: 28.93% | SUE: 0.85 | # QB: 3
EPS next Quarter (2026-06-30): EPS=1.99 | Chg7d=+0.000 | Chg30d=-0.231 | Revisions Net=-7 | Analysts=14
EPS current Year (2026-12-31): EPS=7.95 | Chg7d=+0.000 | Chg30d=-1.193 | Revisions Net=-13 | Growth EPS=+24.4% | Growth Revenue=+20.4%
EPS next Year (2027-12-31): EPS=9.71 | Chg7d=+0.124 | Chg30d=-1.016 | Revisions Net=-10 | Growth EPS=+22.1% | Growth Revenue=+10.6%
[Analyst] Revisions Ratio: -0.78 (1 Up / 8 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.6%)
[Growth] Growth Spread = +19.1% (Analyst 23.5% - Implied 4.4%)